The 'cannabinoid hypothesis' of schizophrenia tulates that over-activity of the endocannabinoid system might contribute to the aetiology of schizophrenia. In keeping with this hypothesis, increased expression of CB 1 receptors, elevation of the endocannabinoid anandamide (AEA) and cannabinoidinduced cognitive changes have been reported in animal models of schizophrenia and psychotic patients. In this study we measured brain endocannabinoid levels and [
Introduction
The 'cannabinoid hypothesis ' of schizophrenia was originally based on the observation that the psychotomimetic ingredient of marijuana, delta-9-tetrahydrocannabinol can exacerbate psychosis (D 'Souza et al. 2005) , produce perceptual alterations and/or psychotic symptoms in healthy subjects similar to those observed in schizophrenia patients (D 'Souza et al. 2004 ; Emrich et al. 1997) , and be a risk factor for the development of schizophrenia (Arseneault et al. 2002) . Several lines of evidence indicate that over-activity of the endocannabinoid system and alteration of CB 1 receptor function may play a role in the pathophysiology of schizophrenia (D 'Souza, 2007 ; Pryor, 2000) . First, elevation of the endocannabinoid anandamide (AEA) has been reported in the blood (De Marchi et al. 2003) and cerebrospinal fluid (CSF) (Giuffrida et al. 2004 ; Leweke et al. 1999 Leweke et al. , 2007 of schizophrenia patients. Second, t-mortem studies have shown increased CB 1 receptor binding in the anterior (Zavitsanou et al. 2004 ) and posterior (Newell et al. 2006 ) cingulate cortex and prefrontal cortex (PFC) (Dean et al. 2001) , two brain regions implicated in schizophrenia. Third, a triplet repeat (AAT) n polymorphism for the CB 1 receptor gene has been associated with the hebephrenic subtype of schizophrenia (Ujike et al. 2002) . Recently, studies carried out in rat models of schizophrenia have provided additional support for the involvement of the endocannabinoid system in this pathology (Malone et al. 2007 ; Vigano et al. 2008) . Using the social isolation rearing model, Malone and co-workers (2007) showed decreased CB 1 receptor expression in the caudate putamen (CPu) and amygdala, whereas Vigano and colleagues (2008) observed an increase in the ventral tegmental area (VTA) and amygdala of phencyclidine (PCP)-treated rats, as well as an elevation of the endocannabinoid 2-arachidonylglycerol (2-AG) in PFC.
Other studies suggest that an overactive endocannabinoid system may represent a compensatory adjustment to the disease and possibly have a protective role in schizophrenia. Indeed, the AEA elevation observed in the CSF of drug-naive schizophrenia patients has been negatively correlated to psychotic symptoms (Giuffrida et al. 2004 ; Leweke et al. 2007) .
To elucidate the role of the endocannabinoid system in psychoses, we investigated possible changes in endocannabinoid transmission in rats undergoing withdrawal from subchronic PCP, a well-established pharmacological model of schizophrenia (Enomoto et al. 2007 ; Jentsch & Roth, 1999 ; Seillier & Giuffrida, 2009) . Given the ability of the dopaminergic system to modulate endocannabinoid transmission , changes in dopamine (DA) levels were also investigated. We also assessed whether increasing AEA tone [via systemic administration of the fattyacid amide hydrolase (FAAH) inhibitor URB597], or blocking CB 1 receptors (via the CB 1 antagonist AM251) affected the following PCP-induced behavioural deficits : (1) impairment of working memory in a variable-delayed alternation task in a T-maze, (2) social withdrawal, and (3) motor hyperactivity in response to d-amphetamine challenge. As AEA has been shown to have a protective effect in schizophrenia (Giuffrida et al. 2004) , we hypothesize that URB597-induced AEA elevation should ameliorate the behavioural deficits in PCP-treated rats. By contrast, if AEA is not protective, blockade of CB 1 receptors should improve PCP-induced deficits. Animals were treated subchronically with either saline (1 ml/kg) or PCP (5 mg/kg) according to Jentsch et al. (1997) , by intraperitoneal (i.p.) route, twice a day for 7 d, and sacrificed 5 d [post-treatment day (PTD)5] or 10 d (PTD10) after the last drug injection ( Fig. 1) , two time-points corresponding to the beginning and the end of the behavioural battery (Seillier & Giuffrida, 2009) , respectively.
Materials and methods

Drugs
Endocannabinoid measurements
Animals (n=24) were anaesthetized with halothane, their CSF rapidly collected from the cisterna magna using a 27-gauge hypodermic needle. Rats were decapitated and their brains collected, frozen in 2-methylbutane (x45 xC), and stored at x80 xC until use. Frozen brains were placed on a stainless-steel mould (Roboz ; Rockville, USA) kept at x15 xC and sliced into 1-mm coronal sections using razor blades to dissect out the following brain areas : medial PFC (prelimbic and infralimbic cortices), anterior cingulate cortex (aCgCx), CPu, nucleus accumbens (NAc), globus pallidus, thalamus, amygdala, entorhinal cortex, dorsal and ventral hippocampus, VTA and substantia nigra. CSF and tissue samples were spiked with 50 pmol of [ 2 H 4 ]AEA and [ 2 H 5 ]-2-arachidonyl glycerol (internal standards) and processed as previously described (Hardison et al. 2006) . Lipids were extracted by adding methanol/chloroform/water (1 : 2 :1, v/v/v). In the case of tissue samples, the chloroform layer was further purified by solid phase extraction (SPE) using C 18 Bond Elut cartridges (100 mg ; Varian, USA) as previously described (Hardison et al. 2006) . No SPE was applied to CSF samples. Endocannabinoid-containing fractions were analysed by gas chromatography/chemical ionization mass spectrometry (GC/MS) using an isotope dilution assay as previously described (Hardison et al. 2006 ).
Measurements of DA and its metabolites
Tissue samples dissected from the same brain areas reported above were homogenized in 0.1 m perchloric acid (100 ml/10 mg of tissue) and centrifuged at 10000 g for 8 min at 4 xC. Supernatants were analysed by high-performance liquid chromatography (HPLC) to quantify DA and relative metabolites, DOPAC and homovanillic acid (HVA). Analyses were carried out by microbore HPLC using a SphereClone 150-mmr 2-mm column (3-mm packing) with a BAS Unijet cell (Bioanalytical Systems Inc., USA) and a 6-mm diameter glassy carbon electrode at ¡650 mV, connected to an electrochemical detector (INTRO ; Antec Leyden, The Netherlands). The mobile phase consisted of 85 mM sodium acetate, 0.34 mM EDTA, 15 mM sodium chloride, 0.81 mM octanesulphonic acid (sodium salt), 5 % methanol (v/v) (pH 4.85). The flow rate was 220 ml/min and the total runtime 15 min.
Autoradiography
Rat brains (n=32) were rapidly removed at PTD5 or PTD10 (Fig. 1) , frozen on dry ice and stored at x80 xC until use. Coronal sections (20 mm) were cut at x16 xC in a cryostat at the level of the medial PFC (from Bregma 3.2 to 2.2 mm), CPu (1.6 to 1.0 mm), dorsal hippocampus (x3.14 to x3.6 mm) and VTA (x5.2 to x5.3 mm) according to the Paxinos atlas of the rat brain (Paxinos & Watson, 1998) . Sections were thawmounted onto gelatin-coated glass slides, desiccated at 4 xC for 18 h under vacuum and stored at x80 xC until use.
Autoradiography of CP55,940-stimulated [ 35 S]-GTPcS binding in brain sections was performed as previously described (Sim-Selley & Martin, 2002) with slight modifications. Slide-mounted sections were equilibrated in Tris-HCl buffer (50 mM, pH 7.4), supplemented with 3 mM MgCl 2 , 0.2 mM EGTA, 100 mM NaCl, 0.2 mM dithiothreitol and 0.5 % bovine serum albumin (BSA) for 10 min at 25 xC. Sections were pre-incubated in Tris-HCl buffer containing GDP (2 mM) and DPCPX (1 mM (Andersson et al. 2005 ; Fattore et al. 2007 ) with slight modifications to determine the duration of postincubation wash times to obtain the highest percent of specific radioligand binding. Slide-mounted sections were pre-incubated in Tris-HCl buffer (50 mM, pH 7.4), as above and then incubated in 4 nm [
3 H]CP55,940 for 2 h in assay buffer containing 0.5 % BSA. Non-specific binding was determined by incubating adjacent sections with the CB 1 antagonist AM251 (1 mM). Slides were rinsed for 1 h in ice-cold Tris-HCl containing 0.3 % BSA, followed by three washes in cold Tris-HCl (1 h each) and a brief dip in cold deionized water. Sections were dried and exposed to Kodak Biomax MR film (Amersham) for 3-6 wk. Digitized autoradiograms were analysed using the NIH Image version 1.47. [
3 H]CP55,940 binding was quantified using simultaneously exposed [
3 H]-labelled standards (ART-123 ; American Radiochemicals, USA) which had been calibrated according to colleagues (1983, 1985) . The amount of ligand bound was determined by converting optical density measurements to femtomoles per milligram of protein. 
Behavioural testing and drug treatment
Rats (n=48) were tested 36 h after the last drug (or vehicle) injection using a previously published behavioural battery (Seillier & Giuffrida, 2009 ; see The behavioural measurements were separated from each other by 1-d intervals. In each test (i.e. day 12 for working memory, day 14 for social interaction, and day 17 for motor activity) animals received an acute i.p. injection of either vehicle (Tween-80/PEG/saline, 5/5/90, 1 ml/kg), URB597 (0.3 mg/kg), or AM251 (1 mg/kg), 1 h before the behavioural test (or just before the habituation period in the motor activity test). The dose and timing of URB597 and AM251 were chosen from previous in-vivo studies (Fegley et al. 2005 ; Laviolette & Grace, 2006 ; Morgese et al. 2007 ; Solinas et al. 2006) .
Working memory
Working memory was measured using a discrete paired-trial delayed alternation paradigm in a T-maze (modified from Aultman & Moghaddam, 2001) . The arms of the T-maze were made of black acrylic (15r30r40 cm, w/h/l). The main alley was 65 cm long. Movable guillotine doors separated (a) the main alley from the start box, (b) each side arm from two goal boxes at the end of the arms, both baited with food (Honey Nut Cheerios). Each side arm also had a door to open/close the entrance. A holding cage adjacent to the T-maze was used to host the animals in the inter-trial intervals (2-min), during which the maze was wiped clean with 10 % alcohol. All experiments were carried out without food restriction.
A 12-d-long training for the delayed alternation task preceded the drug treatment. Details on the training are provided elsewhere (Seillier & Giuffrida, 2009) . At the end of drug treatment, animals were tested for 3 d on the discrete alternation task (no delay) and for 1 d on the delayed alternation task (PTD5) consisting of a forced run (access to only one arm), and a choice run (access to both arms ; only the arm opposite to the one visited during the forced run was baited). Animals had to enter the baited arm to succeed. The animals had 10 s to consume food ; during this time, the maze was wiped clean to remove any olfactory cues. An intra-trial delay of either 0 (no delay) or 60 s separated each forced run from a choice run. The 60-s delay was selected from previous data (Jentsch et al. 1997 ; Seillier & Giuffrida, 2009) . One hour before the delayed alternation task, rats received an acute administration of either vehicle, URB597 or AM251. Criterion for the discrete alternation task was defined as a success rate of 80 %.
Social interaction
Social withdrawal was tested using the social interaction test (adapted from Sams-Dodd, 1998a), 7 d after the last drug injection (Fig. 1) . As previously described (Seillier & Giuffrida, 2009 ), animals were tested in pairs (two unfamiliar rats receiving the same treatment and housed in different home cages) and matched up according to their body weights. Rats received an acute administration of either vehicle, URB597 or AM251 1 h before the test, and were then placed simultaneously into an unfamiliar arena (made of black acrylic ; dimensions : 100r100r40 cm) and their behaviour recorded for 60 min. A score of 1 point was assigned to each of the following behavioural occurrences : (1) investigative sniffing (sniffing the conspecific's snout or other parts of the body) ; (2) following (rat moves towards and follows the conspecific) ; (3) climbing over or under (climbing over the conspecific's back or pushing the head and forepart of the body beneath the conspecific).
Motor activity
Various parameters (e.g. distance travelled, number of rearings, time spent in the centre of the box, motor speed) were recorded using the ActiMot Activity Measuring System version 6.07 (TSE Systems GmbH, Germany).
Nine days after the last drug injection (Fig. 1) , animals were placed in the Actimot boxes for 60 min to assess their motor activity in response to a novel environment. All rats then received a saline injection (1 ml/kg i.p.) as a mild stressor and were monitored for additional 120 min. The following day, animals were returned to the Actimot boxes immediately after receiving an acute administration of either vehicle, URB597 or AM251. After 60 min, they received a d-amphetamine injection (1 mg/kg i.p.) and their motor activity was measured for 120 min.
Statistical analyses
Neurochemical and autoradiography data were analysed by two-way ANOVA with treatment (saline, PCP) and time (PTD5 or PTD10) as between-subject factors. Dose-response curves for CP55,940-stimulated [
35 S]GTPcS binding were fitted by nonlinear regression using the KaleidaGraph software (version 4.0.1, Synergy Software, USA) according to the model :
where E is the response at the CP55,940 concentration [A], E max is the maximal response, EC 50 is drug concentration that yields a half-maximal response, and n is the slope factor. The effect of AM251 or JTE907 on CP55,940-stimulated [ 35 S]GTPcS binding was analysed by one-way ANOVA, followed by NewmanKeuls test.
Data from the discrete alternation test were analysed by two-way ANOVA with treatment (saline, PCP) as between-subject factor and time (day) as repeated measure factor. The delayed alternation data, as well as social interaction and motor activity, were analysed by three-way ANOVA with treatment (saline, PCP) and drug (vehicle, URB597, AM251) as between-subject factors and delay (0, 60 s) or time (10-min intervals) as within-subject factor. The Newman-Keuls test was used for post-hoc comparisons when required. The level of significance was set at p<0.05.
Results
Endocannabinoid measurements
PCP-treated rats (n=24) showed a significant increase in AEA levels in the NAc ( Fig. 2a ; main effect of treatment : F 1,17 =5.08, p<0.05). A similar trend although not significant was observed in the medial PFC (Table 1) . We also observed a significant 2-AG elevation in the VTA at PTD10 (Fig. 2b, p<0. 01 ; treatmentrtime interaction : F 1,18 =4.35, p=0.05), whereas there was no change of either AEA or 2-AG levels in other brain areas (Tables 1 and 2 ) nor in the CSF (Fig. 2c) at any of the time-points examined.
DA measurements
DA and its metabolites were measured in the same brain areas collected from the rats used for endocannabinoid quantifications (contralateral hemisphere). DA levels were unchanged throughout the brain with the exception of the amygdala at PTD10 antagonist JTE907 (100 nM). AM251 markedly reduced CP55,940-stimulated [ 35 S]GTPcS binding, whereas JTE907 had no effect (Fig. 3) , thus indicating that, in the brain, CP55,940 is mainly acting at CB 1 .
The effect of subchronic PCP on the functional coupling of CB 1 receptors to G proteins was studied in an independent group of rats (n=32). CP55,940-stimulated [
35 S]GTPcS binding was increased in aCgCx (Fig. 4a, p<0 .05 ; treatmentrtime interaction : F 1,27 =6.78, p<0.05) and NAc (Fig. 4b, p<0 .05 ; treatmentrtime interaction : F 1,26 =5.02, p<0.05) of PCP-treated rats at PTD5, but returned to control levels at PTD10. On the other hand, we observed decreased binding in the CA2/3 region of the hippocampus at PTD10 (Fig. 4c, (Table 4) .
Behavioural studies
Performance in the alternation task (days 9-11) was >80 % criterion and improved over the 3 d testing (F 2,74 =11.50, p<0.0001, data not shown). Subchronic PCP did not affect this behavioural measure before the exposure to URB597 or AM251. The percentage of correct responses (Fig. 5a, PTD5 ) decreased as a function of the delay duration (F 1,37 =112.11, p<0.0001) in all treatment groups. As expected, the impairment at 60-s delay was more severe in PCP-than in salinetreated rats (p<0.05). The PCP-induced deficit was attenuated by AM251 (p<0.05), but not URB597 (Fig. 5a) . Interestingly, both URB597 and AM251 impaired this task in saline-treated animals at 60-s delay (p<0.05 and p<0.01, respectively) in a way similar to PCP, whereas no deficits were observed without delay. A pattern similar to that of URB597 was obtained with the cannabinoid transport blocker OMDM-2 (5 mg/kg, same regimen as URB597, data not shown), a drug that also elevates brain AEA levels (de Lago et al. 2005) .
PCP-treated rats spent significantly less time in social interaction (Fig. 5b, p<0.05) , showing a decrease in the number of sniffing (p<0.05) and climbing (p<0.05) episodes (data not shown). The PCP-induced social withdrawal was reversed by URB597 (p<0.01). However, this drug reduced social interaction in saline-treated controls (p<0.05). A similar effect was obtained with OMDM-2 (5 mg/kg, data not shown). AM251 did not affect this behavioural measure in either saline-or PCP-treated animals. However, pretreatment with AM251 blocked URB597 effect in PCPtreated rats (time spent in interaction : URB597, 1108¡11 s ; URB597+AM251, 845¡44 s ; p<0.001), but not in saline-treated rats (URB597, 868¡31 s ; URB597+AM251, 755¡64 s ; p>0.05) ; three-way ANOVA followed by Newman-Keuls post-hoc (n=8 for each experimental group ; time spent in interaction by control rats : 1115¡53 s). At this dose, URB597 was equally effective in increasing AEA levels in the CPu, an area known to express FAAH (Maccarrone et al. 2008) , in either saline-and PCP-treated rats (78 % and 86 % increase over control, respectively ; n=8, p<0.05 each ; two-way ANOVA followed by Newman-Keuls post-hoc).
PCP-treated rats did not differ from salinetreated controls in distance travelled in response to d-amphetamine (Fig. 5c ) nor in any of the other motor parameters measured (data not shown). No significant changes were observed after AM251 or URB597 (Fig. 5c) . Although not significantly, AM251 tended to reduce motor velocity (F 1,41 =3.38, p=0.07), percent time spent in hyperactivity (F 1,41 =3.33, p=0.08) and in movement (F 1,41 =3.25, p=0.08 ) in saline-treated rats (data not shown).
Discussion
Our study shows a localized enhancement of endocannabinoid levels in rats subchronically treated with PCP. Specifically, we observed increased 2-AG in the VTA 10 d after withdrawal from PCP and a slight elevation of AEA in NAc throughout the experiment. Although we found altered CB 1 receptor-stimulated [
35 S]GTPcS binding in areas relevant to schizophrenia following PCP treatment, basal [ 35 S]GTPcS binding was also affected in the same regions. CB 1 receptorbinding sites remained unchanged. PCP-induced working-memory deficit and social withdrawal were reversed by the CB 1 antagonist AM251 and the FAAH inhibitor URB597 in a CB 1 -dependent fashion, respectively. Paradoxically, these drugs produced some behavioural impairment in saline-treated rats, suggesting that alterations of endocannabinoid transmission in untreated rats may produce detrimental effects similar to those observed after subchronic PCP.
To date, disturbances of endocannabinoid transmission have been reported in only two animal models of schizophrenia (Malone et al. 2007 ; Vigano et al. 2008) . Malone et al. (2007) observed CB 1 receptor down-regulation in the CPu and amygdala, and FAAH up-regulation in the CPu and NAc of rats undergoing social isolation. On the other hand, Vigano and colleagues (2008) reported increased CB 1 expression in the VTA and amygdala, and elevated 2-AG in the PFC of rats exposed to chronic intermittent PCP treatment. They also found altered CB 1 receptorstimulated [
35 S]GTPcS binding in the PFC, hippocampus, substantia nigra, cerebellum and globus pallidus. The discrepancies between these and our data may be attributed to differences in drug regimen (intermittent vs. repeated PCP ; 5-10 d vs. 72-h withdrawal) and age of subjects (juvenile vs. adult rats). In addition, Vigano et al. measured endocannabinoid levels immediately after the behavioural tasks, whereas our measurements were carried out in a separate group of rats that did not undergo behavioural testing and probably reflect endocannabinoid basal values. This difference in the experimental design may be crucial as endocannabinoids are produced 'on demand ' in response to neuronal activity (Piomelli, 2003) . The mechanisms and source(s) responsible for 2-AG increase in the VTA remain undetermined and may be linked to parallel increases of DA levels and turnover in the amygdala and PFC, respectively. Indeed, there are (Floresco & Tse, 2007 ; and electrophysiological data show that DA neurons in the VTA can release 2-AG after PFC stimulation (Melis et al. 2004 ).
On the other hand, AEA elevation in NAc may reflect an increase of dopaminergic transmission in this brain area, as indicated by the elevated HVA 5 d after PCP withdrawal, which in turn could lead to AEA increase via stimulation of DA D 2 receptors .
In previous studies, we found elevated AEA in the CSF of drug-naive schizophrenia patients (Giuffrida et al. 2004 ; Leweke et al. 1999 Leweke et al. , 2007 . By contrast, PCP-treated rats showed no changes in CSF AEA. This discrepancy may depend on differences in the neurochemistry of schizophrenia and corresponding animal models. For example, first-episode schizophrenia patients have increased striatal DA neurotransmission (Laruelle et al. 1996 (Laruelle et al. , 2003 and the AEA elevation observed in these patients may be a consequence of striatal hyperdopaminergia . By contrast, we found no significant changes of striatal DA in PCP-treated rats.
Our data showed no changes in CB 1 receptor expression but increased receptor-stimulated [
35 S]GTPcS binding in aCgCx and NAc and a reduction in the CA2/3 fields of the hippocampus of PCP-treated rats. The result in aCgCx is in line with a previous report showing increased CB 1 receptor binding in this area in schizophrenia patients (Zavitsanou et al. 2004) . However, the changes in CB 1 receptor function observed in our study have to be viewed cautiously as basal [
35 S]GTPcS binding was also altered in these regions.
As previously reported (Jentsch et al. 1997 ; Marquis et al. 2007 ; Seillier & Giuffrida, 2009) , withdrawal from subchronic PCP caused a delay-dependent impairment of working memory. In this study, we showed that AM251 reversed the PCP-induced workingmemory deficit, but worsened this behavioural measure in saline-treated rats. CB 1 receptors are abundant in the PFC (Egerton et al. 2006 ), a brain region implicated in the delay-dependence of workingmemory tasks (Delatour & Gisquet-Verrier, 1999) , and modulate neural transmission in this area (Egerton et al. 2006) . In agreement with the hypo-frontality hypothesis of schizophrenia (Manoach, 2003) and the observation that chronic PCP decreases PFC activity (Morris et al. 2005) , inhibition of CB 1 receptors might facilitate glutamatergic transmission in the PFC by reversing the CB 1 -mediated suppression of excitatory post-synaptic currents (Auclair et al. 2000) . Interestingly, Vigano et al. (2008) showed increased 2-AG in the PFC of PCP-treated rats after performing in the novel object recognition test, a PFC-dependent task. Therefore, CB 1 receptor blockade might limit the effect of excessive 2-AG and consequently alleviate the observed behavioural impairment. In addition, since steady dopaminergic activity is important for optimal PFC-dependent cognition (Murphy et al. 1996) and given the fact that PFC stimulation reduces DA neuron firing in the VTA via 2-AG (Melis et al. 2004) , blockade of CB 1 receptors in PCP-treated rats may counteract the suppressive effect of 2-AG in the VTA, thus restoring normal DA transmission in the PFC. By contrast, in saline-treated rats, AM251 may increase DA in the PFC above physiological levels and possibly produce a cognitive deficit.
Our study supports the current view that stimulation of the cannabinoid system impairs working memory in a variety of behavioural paradigms (for review, see Egerton et al. 2006) . In keeping with these observations, systemic administration of URB597 or OMDM-2, two drugs that elevate endocannabinoid tone in the brain (de Lago et al. 2005 ; Fegley et al. 2005) , caused a working-memory deficit in saline-treated rats. These compounds, however, did not enhance the PCP-induced deficit, possibly because of a ceiling effect.
As expected (Lee et al. 2005 ; Qiao et al. 2001 ; Seillier & Giuffrida, 2009 ), we observed reduced social interaction after withdrawal from subchronic PCP. This deficit was reversed by URB597 and OMDM-2. Surprisingly, these compounds decreased social interaction in saline-treated rats. Hypo-locomotion or increased anxiety are unlikely to account for the observed effects of URB597 since this drug : (1) did not affect any of the motor parameters analysed in this and other studies (Hill et al. 2007 ; Jayamanne et al. 2006) ; (2) decreases (rather than increases) anxiety at this dosage (Hill et al. 2007 ; Moise et al. 2008) . In addition, there is general agreement that PCP-induced social withdrawal in rats does not reflect increased anxiety (Enomoto et al. 2007 ; Lee et al. 2005 ; SamsDodd, 1998b ) and is not reversed by the anxiolytic agent chlordiazpoxide (Snigdha & Neill, 2008) . The diverging URB597-induced effects on social interaction observed in saline-vs. PCP-treated rats may be attributed to differences in endocannabinoid levels between these two experimental groups when engaged in behavioural tasks (despite the similar basal levels found under resting conditions). In particular, URB597 might increase endocannabinoid tone in PCP-treated rats to a level sufficient to restore normal function, but elevate brain endocannabinoids in saline-treated animals above physiological levels, leading to a behavioural deficit. This hypothesis is currently under investigation. As previously reported (Trezza & Vanderschuren, 2007) , we did not observed any disruptive effect of AM251 on social interaction in either saline-or PCP-treated rats. However, this compound reversed the beneficial effect of URB597 in PCP-treated rats, but not URB597-induced social withdrawal in saline-treated rats. Preliminary data in our laboratory suggest that the later effect is blocked by the TRPV1 antagonist capsazepine (A. Seillier et al., unpublished observations). Thus, additional research is needed to understand the molecular mechanisms underlying the divergent effects of URB597 in these experimental groups.
In agreement with other studies (Collins et al. 2006 ; Egerton et al. 2008 ), we did not find sensitization of amphetamine-induced motor responses in PCPtreated rats. As previously reported (Corbille et al. 2007 ; Hill et al. 2007 ; Thiemann et al. 2008a ; Trezza & Vanderschuren, 2007) , URB597 or AM251 did not affect spontaneous motor activity when administered alone. In addition, our data confirmed the report from Thiemann et al. (2008a) showing lack of effect of AM251 on amphetamine-induced hyperactivity. On the other hand, these results differed from behavioural experiments carried out with the CB 1 antagonist SR141716A which enhances motor responses following amphetamine challenge (Masserano et al. 1999 ; Thiemann et al. 2008 b) , suggesting that the SR141716A effect might depend on the blockade of other cannabinoid-like receptors (Thiemann et al. 2008a) . In agreement with this hypothesis, genetic ablation of CB 1 receptors does not affect either spontaneous or amphetamine-induced motor activity (Houchi et al. 2005 ; Thiemann et al. 2008b ).
In conclusion, subchronic PCP did not cause any remarkable changes in endocannabinoid transmission, with the exception of altering AEA and 2-AG levels in NAc and VTA, respectively. Nevertheless, pharmacological manipulation of the endocannabinoid system had dramatic consequences on behavioural measures relevant to schizophrenia, thus indicating a role for this system in psychoses. Indeed, URB597-induced endocannabinoid enhancement, precipitated psychotic-like behaviours in normal rats, but ameliorated PCP-induced social withdrawal, thus supporting the observation that endocannabinoids' elevation may have a protective effect in schizophrenia (Giuffrida et al. 2004 ; Leweke et al. 2007) . Similarly, CB 1 antagonism had a detrimental effect on cognition under normal conditions, but ameliorated PCP-induced deficit. Further studies are necessary to elucidate the pharmacological and molecular mechanisms responsible for these divergent effects.
